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Changes in chlamydia prevalence and duration of infection inferred from testing and diagnosis rates in
) Test performance parameters are beta-distributed based on literature studies with parameters (α, β) as given, equal to one plus the numbers of positive and negative results in the study, respectively. The rates of spontaneous recovery and treatment seeking were sampled using MCMC methods (see main text). The proportion of the population who were sexually active is a beta distribution with parameters such that its central 95% credible interval matches the 95% confidence interval for the proportion estimated from Natsal-3. The proportion of incident infections which are asymptomatic was calibrated so that the sampled prevalence in 15-24-year-olds matched the Natsal estimates (see main text). The plots show the good agreement between the population-based Natsal prevalence surveys and our model-based method, informed by surveillance data. For men in Natsal-2 the higher prevalence estimated from the survey vs the surveillance data is likely to be because only those aged 18+ years were included in Natsal-2, and prevalence in younger ages is much lower.
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Supplementary Figure 2:
Sensitivity of sampled prevalence and average duration of infection to sampled treatment-seeking rate by symptomatic individuals. The plots use samples for testing and diagnosis rates from distributions corresponding to 15-19-year-old men and women in 2012 (the year to which the model was calibrated). For each sample, shown as a dot, the x-coordinate indicates the treatment-seeking rate, sampled from a uniform distribution. The y-coordinate indicates the sampled prevalence (upper panels) or average duration of infection (lower panels).
Both inferred quantities are insensitive to the sampled treatment-seeking rate for all rates above ~5 per year, corresponding to an average time to treatment of <2 months. Hence, if the average time to treatment for symptomatic infections is less than two months, which seems likely in all ages and risk groups, the inferred results are insensitive to the rate of treatment seeking.
